Habib™ 4X Device Yields Less Blood Loss and Shorter Operative Time in Study
The study – published in the Journal of Urology – also showed 91% fewer adverse events and a 16% shorter operative time when using the Habib 4X.
The Habib 4X – manufactured and marketed by AngioDynamics (NASDAQ: ANGO) – delivers radio frequency energy through electrode needles, coagulating tissue along a path then followed to surgically cut out and remove the lesion. By cauterizing the blood vessels excessive bleeding and other complications can be avoided compared to other methods.
“Our results show the Habib 4X radio frequency device can yield a significant benefit during open nephron sparing surgery, including reduced blood loss and a faster operative time,” said Dr. Wesley M. White, the chief author of the study. “We believe these and other key results from this study will be very helpful to physicians looking for better ways to conduct this increasingly common procedure.”
Ninety patients underwent open nephron sparing surgery, during which the surgeon resected sections of the kidney with tumors but other portions of the treated kidney were preserved. Half were treated with the Habib 4X radio frequency resection device and half with blood flow controlled with foam bolsters, suture ligation and Bovie electrocautery.
The study, titled “Nephron Sparing Surgery Using a Bipolar Radio Frequency Resection Device,” was authored by Wesley M. White, Frederick A. Klein and W. Bedford Waters from the Division of Urologic Surgery, University of Tennessee Medical Center, Knoxville, Tennessee, and published in the December edition of the Journal of Urology. “This data reinforces the meaningful improvement the Habib 4X represents over alternatives in terms of reduced blood loss, complications and operative times, providing significant advantages to both physicians and patients,” said Jan Keltjens, President and CEO of AngioDynamics. “This device is an important part of the surgical oncologist’s black bag. As the leader in radio frequency resection technology, we look forward to further controlled trials comparing radiofrequency resection versus standard treatment options to continue to reinforce the clinical benefit of this approach.”
AngioDynamics, Inc. (“AngioDynamics” or the “Company”) is a leading provider of innovative medical devices used by interventional radiologists, surgeons and other physicians for the minimally invasive treatment of cancer and peripheral vascular disease. The Company’s diverse product line includes market-leading radiofrequency ablation and irreversible electroporation resection systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.angiodynamics.com.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “potential,” or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from the Company’s expectations. Factors that may affect the actual results achieved by the Company include, without limitation, the ability of the Company to develop its existing and new products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of the Company to execute its leadership development plan and integrate purchased businesses, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2008. The Company does not assume any obligation to publicly update or revise any forwardlooking statements for any reason.